Paul Studenic

MD PhD│ Clinician in Internal Medicine and Rheumatology │ Clinical and translational Researcher │ @ARD_BMJ │ @oegrr │ @EULAR_JC

[STRATA-FIT @STRATA_FIT]

Day 1 of the #STRATAFIT General Assembly Meeting is underway! The consortium is coming together to review progress, align on key milestones, and shape the next steps for the project.

Stay tuned for updates!

[STRATA-FIT @STRATA_FIT]

Tomorrow, #STRATAFIT consortium kicks off its General Assembly Meeting in London! We'll be bringing together consortium partners & members of the Patient Advisory Panel for a key moment of collaboration and exchange.

Do you have any questions for us?👇

[STRATA-FIT @STRATA_FIT]

STRATA-FIT will be present at @eular_org 2026 Congress in London! Come & learn more about our work on #D2TRA and the latest developments across our projects.

Our booth will be O19, located in the NPO area (level 3) close to the Session rooms.
We look forward to see you! 💂

[RMD Open @bmj_rmdopen]

🚬 Heat-not-burn tobacco: biologically neutral for #RA risk?

In bronchial epithelial cells, heat-not-burn cigarette extract, like traditional cigarette extract, increased:
✅ Protein citrullination
✅ Protein carbamylation
✅ Apoptosis, shown by annexin V/PI and cleaved PARP1

These RA-related mechanisms raise concern that “smoking alternatives” may not be biologically neutral in rheumatology.

🔓 https://t.co/1Fj9vUqUKX

[STRATA-FIT @STRATA_FIT]

We are thrilled to announce that the first patient has been enrolled in ACCESS-STRATA, the clinical study of STRATA-FIT, at @UMCUtrecht . Following the Site Initiation Visits that began in March, this marks a key milestone for the study.

[STRATA-FIT @STRATA_FIT]

Development of digital decision-support tool for healthcare professionals:
-Alert clinicians when a patient may have D2TRA
-Support personalised treatment based on patient subtype, clinical characteristics & patient preference
The tool will be evaluated in a pilot clinical study

[EULAR @eular_org]

Today is Rare Disease Awareness Day!

🤝At #EULAR, we stand with everyone living with rare rheumatic diseases — conditions that are often overlooked, underdiagnosed, and misunderstood.

Together, let’s raise awareness to promote earlier diagnosis and better access to care.

[STRATA-FIT @STRATA_FIT]

STRATA-FIT: Your new hub for D2T-RA insights

Exciting update! Our website has been transformed into your ultimate resource for:
Latest project news
Cutting-edge research on D2T-RA
Patient perspectives
Clinical insights
Upcoming events

👉 Explore now: https://t.co/ZzCIPVqTl8

[EULAR @eular_org]

🚀Join us on the EULAR webinar with Quality of Care: "Quality indicators", explaining how they are developed, implemented, measured, adapted over time, and prioritised, with practical examples.

💻 19 March 2026, 17:00 - 18:00 CET

Register here 👉 https://t.co/Z7ljmjdStd

[RMD Open @bmj_rmdopen]

🔬 The TREAT EARLIER trial investigated which arthralgia patients with subclinical inflammation respond best to a 1-year course of methotrexate treatment.
📊 Only 38% of treated patients achieved MRI-defined response. Responders were identified by higher baseline subclinical inflammation, particularly multiple sites of tenosynovitis (PPV 77–79%).
💡 Results support a precision medicine approach: arthralgia patients with extensive subclinical tenosynovitis/osteitis may benefit most from early methotrexate intervention.

🔗 https://t.co/oO60hUkB8N

[RMD Open @bmj_rmdopen]

🔄🩺 Relapse patterns in Granulomatosis with Polyangiitis matter for risk counselling.

In 795 patients, organ involvement at diagnosis strongly predicted relapse in the same organ (ENT, lungs, kidneys, eyes, CNS).

🔹 56% relapsed only in initially involved organs
🔹 New organ disease was uncommon and rarely isolated
🔹 Certain baseline features lowered risk of new-organ relapse

Useful data to personalise follow-up and patient counselling
🔗https://t.co/BBfcNgug4J

[STRATA-FIT @STRATA_FIT]

STRATA-FIT New Year Wishes 2026: Challenging RA Differently

For years, challenging RA cases lacked clear guidance. Our D2T framework is changing that. In 2026, we're setting new standards for understanding and treating complex rheumatoid arthritis.

[RMD Open @bmj_rmdopen]

🧬 Who is really “at risk” of RA among first-degree relatives?

In the SCREEN-RA cohort (n=1544 RA- first-degree relatives , mean follow-up 7.1 yrs):
✅ 27 developed RA (1.7%)
✅ 126 developed seropositive inflammatory arthritis (8.2%)
Using a balanced random forest model:
🔹 High sensitivity (≥0.82), but modest specificity
🔹 Top predictors of future RA:
• Rheumatoid factor
• EULAR clinically suspected arthralgia symptoms
• Multiple affected family members
🔹 For seropositive IA, age, gender and anti-RA33 autoantibodies were most important

🔓 https://t.co/dwJiSmAlCk

[Paul Studenic @Stiddyo]

@STRATA_FIT The upcoming year will be exciting - Putting ideas in Action on the federated platform 😀

[STRATA-FIT @STRATA_FIT]

Our team is making significant strides in #D2TRA research. Data extraction is progressing across 6 centers, w/ harmonized datasets installed in 5 sites.
Initial analyses reveal consistent patterns in #D2TRA distribution, bringing us closer to understanding this complex condition.

[Maria Tektonidou @MariaTektonidou]

The development and validation of a EULAR disease activity score in #Antiphospholipid syndrome.
Honored to chair this EULAR Task Force with the contribution of an international group of #APS experts/Collaborators, patients with APS, and HPRs. https://t.co/tq2bDGcwHb

[EULAR @eular_org]

🌟Are you living with a rheumatic and musculoskeletal disease and want to bring the patients’ perspective in rheumatology research? Join the 4th EULAR Online Course for Patient Research Partners!

📅Learn more and register before 30 November 2025 here👉https://t.co/u3EyZXgK8h

[STRATA-FIT @STRATA_FIT]

Considering patient goals, lifestyle & lived experiences. Supporting clinicians in making complex treatment decisions.
Individualized care is not just a goal. Let’s learn, share, & build a more inclusive world!

https://t.co/Xr7WqDL93b
#RMDreams #WAD2025 #WorldArthritisDay #EULAR

[Paul Studenic @Stiddyo]

Die @oegrr erweitert ihre Kommunikationsbandbreite!

#Podcasts zu einer Vielfalt von #Rheuma Themen werden für alle Interessierte über den Herbst hinweg gelaunched werden

https://t.co/UnSohf8oSh

[EULAR @eular_org]

🚀Join EULAR webinar with QoC: "Points to consider when considering starting targeted therapies in patients with inflammatory arthritis and a recent history of cancer"

🖥️Thursday, 16 October 2025, 18:00 - 19:00 CEST

Register here 👉https://t.co/47USjjsAb6

#Rheumatology #QoC